Abstract

BackgroundTo date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.Methodology/Principal FindingsUsing microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression.ConclusionsOur observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.

Highlights

  • Discovery of sensitive and specific minimally invasive biomarkers that can be exploited to detect early neoplastic changes, facilitating the detection of breast cancer at an early stage, is one of the most important challenges in the management of breast cancer

  • Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer

  • The Caucasians Americans (CAs) study participants (15 CA cases and 15 CA controls) included in Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation analysis were obtained from Data Bank and BioRepository (DBBR), but they were different from the ones used in microRNA profiling

Read more

Summary

Introduction

Discovery of sensitive and specific minimally invasive biomarkers that can be exploited to detect early neoplastic changes, facilitating the detection of breast cancer at an early stage, is one of the most important challenges in the management of breast cancer. The development of minimally or noninvasive, highly sensitive and specific breast cancer biomarkers which can complement and improve on current strategies for breast cancer detection is urgently needed. There are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call